JOSE LUIS GORRIZ TERUEL-rekin lankidetzan egindako argitalpenak (16)

2024

  1. Urinary Cell Cycle Arrest Biomarkers and Diuretic Efficiency in Acute Heart Failure

    CardioRenal Medicine, Vol. 14, Núm. 1, pp. 261-269

2023

  1. Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction

    Scientific Reports, Vol. 13, Núm. 1

  2. Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 10, pp. 783-792

  3. Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status

    JACC: Heart Failure, Vol. 11, Núm. 11, pp. 1611-1622

  4. Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction—a substudy of the DAPA-VO2 study

    Frontiers in Cardiovascular Medicine, Vol. 10

2022

  1. Bending oxygen saturation index and risk of worsening heart failure events in chronic heart failure

    European Journal of Heart Failure, Vol. 24, Núm. 11, pp. 2108-2117

  2. Prognostic value of NT-proBNP and CA125 across glomerular filtration rate categories in acute heart failure

    European Journal of Internal Medicine, Vol. 95, pp. 67-73

  3. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): a randomized clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 10, pp. 1816-1826

2021

  1. CA125 but not NT-proBNP predicts the presence of a congestive intrarenal venous flow in patients with acute heart failure

    European Heart Journal: Acute Cardiovascular Care, Vol. 10, Núm. 5, pp. 475-483

  2. Early urinary sodium trajectory and risk of adverse outcomes in acute heart failure and renal dysfunction

    Revista Espanola de Cardiologia, Vol. 74, Núm. 7, pp. 616-623

2020

  1. CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction

    American Journal of Medicine, Vol. 133, Núm. 3, pp. 370-380.e4

  2. Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial-IRON Trial

    Journal of the American Heart Association, Vol. 9, Núm. 4

  3. Refractory congestive heart failure: when the solution is outside the heart

    ESC Heart Failure, Vol. 7, Núm. 1, pp. 311-314

  4. Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes

    ESC Heart Failure, Vol. 7, Núm. 6, pp. 3792-3800

2018

  1. Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study

    Clinical Cardiology, Vol. 41, Núm. 4, pp. 476-480

  2. Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality

    Circulation, Vol. 137, Núm. 13, pp. 1320-1330